fingolimod / Generic mfg. 
Welcome,         Profile    Billing    Logout  

15 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fingolimod / Generic mfg.
2012-000411-91: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod Untersuchung der natürlichen Killer (NK-) Zellen in Patienten mit Multipler Sklerose unter Fingolimod-Behandlung

Ongoing
4
40
Europe
Gilenya®, Gilenya®, Gilenya®, Gilenya®
Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin, Novartis
relapsing-remitting multiple sclerosis
 
 
2014-000296-12: Voidaanko aivojen mikroglia-solukon aktiivisuutta vähentää ms-potilaan aivoissa?

Ongoing
4
10
Europe
Fingolimodi, Gilenya, Gilenya
Turku University Hospital, Novartis
Multiple sclerosis MS-tauti
 
 
2017-000559-26: A multicentric, international study in order to compare the effectiveness of fingolimod versus dimethyl-fumarate on patients with Multiple Sclerosis. Studio multicentrico, internazionale volto a confrontare l'efficacia di fingolimod e dimetil-fumarato in pazienti con Sclerosi Multipla

Ongoing
4
1360
Europe
Capsule, hard, Gastro-resistant capsule, hard, GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE, TECFIDERA - 240 MG - CAPSULA RIGIDA GASTRORESISTENTE - USO ORALE - BLISTER (PVC/PE/PVDC-PVC ALLUMINIO) - 56 CAPSULE
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Patient-Centered Outcomes Research Institute
relapsing-remitting multiple sclerosis sclerosi multipla recidivante-remittente, multiple sclerosis sclerosi multipla, Diseases [C] - Nervous System Diseases [C10]
 
 
2012-000674-31: A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya®

Not yet recruiting
4
100
Europe
Fingolimod, FTY720, Capsule, hard, Gilenya
Novartis Pharma GmbH, Novartis Pharma GmbH
RNFLT in Patients with relapsing remitting Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
SPRING, NCT04480853: Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Recruiting
4
30
RoW
Fingolimod, FTY720
Novartis Pharmaceuticals
Multiple Sclerosis
01/26
01/26
NCT04667949: Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

Active, not recruiting
4
98
RoW
Fingolimod 0.5mg, FTY720
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis (RMS)
03/25
03/25
PARADIGMS, NCT01892722 / 2011-005677-23: Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Checkmark PARADIGMS
Sep 2017 - Sep 2017: PARADIGMS
Recruiting
3
235
Europe, Canada, US, RoW
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Novartis Pharmaceuticals
Multiple Sclerosis
07/17
07/29
2020-004431-24: A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis Estudio para evaluar la eficacia, seguridad, farmacocinética y farmacodinamia de ponesimod frente a fingolimod durante 108 semanas de tratamiento en pacientes pediátricos, de 10 a <18 años, con esclerosis múltiple remitente recurrente.

Ongoing
3
212
Europe, RoW
Ponesimod, Fingolimod, JNJ-67896153/ACT-128800, Film-coated tablet, Capsule, Gilenya hard capsules
Janssen-Cilag International NV, Janssen Research & Development, LLC
Relapsing-remitting Multiple Sclerosis Esclerosis múltiple remitente recurrente., Chronic inflammatory disease attacking the CNS Enfermedad inflamatoria crónica que ataca al SNC., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT06408259: Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Not yet recruiting
3
194
US
Ozanimod, Fingolimod, Placebo
Celgene
Multiple Sclerosis, Relapsing-Remitting
04/31
07/36
ARTIOS, NCT04353492 / 2019-001341-40: An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Active, not recruiting
3
564
Europe, Canada, US, RoW
Ofatumumab, OMB157
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
04/25
04/25
Operetta 2, NCT05123703 / 2020-004128-41: A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis

Recruiting
3
171
Europe, Canada, US, RoW
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Hoffmann-La Roche, PPD
Relapsing-Remitting Multiple Sclerosis
07/25
09/29
NEOS, NCT04926818 / 2020-002700-39: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Recruiting
3
120
Europe, Canada, US, RoW
Fingolimod, FTY720, Ofatumumab, OMB157, Siponimod, BAF312, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Novartis Pharmaceuticals
Multiple Sclerosis (MS)
03/27
12/31
NCT05423769: Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

Active, not recruiting
N/A
30
RoW
Fingolimod, Sphingomod®, Hikma
Hikma Pharmaceuticals LLC
Relapsing-Remitting Multiple Sclerosis
11/23
05/24
NCT01285479: The Gilenya Pregnancy Registry

Recruiting
N/A
500
Europe, Canada, US, RoW
Fingolimod
Novartis Pharmaceuticals
Multiple Sclerosis
01/31
01/31
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31

Download Options